Primax Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2018
- Revenue Growth 1378.48%
- Profit Growth -19879.65%
- Ebitda -6392.18%
- Net Worth -194.67%
- Total Assets 153.53%
About Primax Pharmaceuticals
Primax Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 April 2013 and has a history of 11 years and nine months. Its registered office is in Dhanbad, Jharkhand, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Renuka Verma, Vinita Bhatia, and Sasmita Mohanty serve as directors at the Company.
Company Details
-
Location
Dhanbad, Jharkhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U37200JH2013PTC002733
-
Company No.
002733
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Apr 2013
-
Date of AGM
29 Sep 2018
-
Date of Balance Sheet
31 Mar 2018
-
Listing Status
Unlisted
-
ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Primax Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Renuka Verma
|
Director | 20-Jan-2022 | Current |
|
Vinita Bhatia
|
Director | 25-Dec-2015 | Current |
|
Sasmita Mohanty
|
Director | 02-May-2022 | Current |
Financial Performance of Primax Pharmaceuticals.
Primax Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 1378.48% increase. The company also saw a substantial fall in profitability, with a 19879.65% decrease in profit. The company's net worth observed a substantial decline by a decrease of 194.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Primax Pharmaceuticals?
In 2017, Primax Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Primaxian Remedies Private LimitedSasmita Mohanty is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Primax Pharmaceuticals?
Unlock and access historical data on people associated with Primax Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Primax Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Primax Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
